Search
Search
Invitrogen
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
Compatible with Direct ELISA
Camoteskimab, also known as AVTX-007, is a monoclonal antibody designed to target and inhibit interleukin-18 (IL-18), a cytokine involved in inflammatory processes. By binding to IL-18, camoteskimab prevents its interaction with its receptor, thereby reducing IL-18-mediated signaling pathways that contribute to inflammation. This mechanism of action positions camoteskimab as a potential therapeutic agent for various inflammatory diseases, including atopic dermatitis. Its development is focused on mitigating the effects of excessive IL-18 activity, which is implicated in the pathology of these conditions. As research and clinical trials progress, camoteskimab holds promise for providing a novel treatment option for patients suffering from chronic inflammatory disorders.
仅用于科研。不用于诊断过程。未经明确授权不得转售。